IBS may be treatable. This test helps you know.
The IBSDetex™ test reliably identifies post-infectious IBS-D and IBS-M
IBS historically has been a diagnosis of exclusion that in some cases could take years. Quest Diagnostics now offers an inclusionary tool to confirm some types of IBS much sooner: IBSDetex. IBSDetex provides physicians and their patients with a quick, simple first-line diagnostic test for post-infectious IBS-D (diarrhea-predominant IBS) and IBS-M (IBS with both diarrhea and constipation).
IBSDetex is a simple blood test with a clear result to include in your IBS diagnostic workup:
- Confirms post-infectious IBS-D and IBS-M with 89% positive predictive value
- 90% specificity1
- Can identify the patients with IBS-D associated with intestinal bacterial overgrowth
- May avoid the unnecessary use of healthcare resources2
- Increased confidence in your diagnosis of IBS
- Specimens analyzed within 72 hours
- From the leading U.S. diagnostic laboratory
|40%||of patients with IBS-D have had |
a prior episode of gastroenteritis
The IBS-gastroenteritis connection
For decades, medical science has struggled to understand the pathogenesis of IBS. But mounting evidence suggests a link to acute gastroenteritis or a recent bout of food poisoning.
- Gastroenteritis-related bacteria produce the neurotoxin CdtB (cytolethal
distending toxin B)
- The immune system produces antibodies that attack CdtB
- These antibodies cross-react with vinculin, a protein lining the intestinal tract
- The lining is degraded, leading to small intestinal bacterial overgrowth (SIBO)
- SIBO manifests as bloating and abdominal pain, the first symptoms of IBS
Based on this new pathogenetic understanding of the disease, researchers have identified and validated two serum biomarkers for diarrhea-prominent IBS: anti-CdtB (cytolethal distending toxin B) and anti-vinculin.
IBSDetex detects anti-CdtB and anti-vinculin1
More than 40% of patients with IBS-D have suffered a previous episode of gastroenteritis.1 IBSDetex measures anti-CdtB and anti-vinculin to confirm post-infectious IBS-D or IBS-M as a source of patient symptoms. These patients may be treatable with antibiotics.
IBSDetex. When the result is clear, you can be, too.
Be in the know sooner, with IBSDetex
|For more information, to order a test or receive test kits for your office, |
contact a Quest Diagnostics Sales Representative.
|Contact us by phone |
Call 1.866.MY.QUEST (1.866.697.8378)
Download the patient brochure
1Pimentel M, Morales W, Rezaie A, et al. Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects. PLOS ONE. 2015;10:e0126438.
2Pimentel M, Purdy C, Magar R, Rezaie A. A predictive model to estimate cost savings of a novel diagnostic blood panel for diagnosis of diarrhea-predominant irritable bowel syndrome. Clin Ther. 2016;38:1638–52.